Literature DB >> 23519049

Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry.

Einat Peles1, Shaul Schreiber, Miriam Adelson.   

Abstract

OBJECTIVES: In 2002, our methadone maintenance treatment (MMT) clinic reached full capacity and admission to treatment was delayed for >1 year. In order to evaluate possible impact of the waiting list on mortality risk of the registered patients, we compared survival after the first 2 years, and long-term survival since registration between admitted and not admitted to our MMT (or other treatment facilities) and to those who admitted immediately, before the establishment of the waiting list in 2002.
METHODS: A total of 608 patients registered between 2002 and 2009. Their vital statistics were obtained from the Israeli National Registry (October 2010).
RESULTS: Of the total 608, 366 registrants (60.2%) were admitted to any treatment (194 [53%] to our MMT, 162 [44.3%] to other MMTs and 10 [2.7%] to other facilities) and 242 (39.8%) were not admitted anywhere. Non admission to treatment when it became available was due to inability to contact the patient (116, 47.9%), self-reported drug discontinuation (44, 18.2%), refusal to follow regulations (39, 16.1%), imprisonment (27, 11.2%), violent behavior (1, 0.4%), death (13, 5.4%), and other (2, 0.8%). The mortality rate (available among 583) during the 2 years on the waiting list was higher (5.0/100 person years) for the 225 non admitted applicants than for the 358 admitted (0.42/100 person years, P < 0.0005) and those who were admitted with no delay before 2002 (2.1/100 person years). The long-term survival between those 3 groups did not differ significantly.
CONCLUSIONS: Opiate addicts are at high risk for mortality during prolonged waiting periods for admission to MMT, indicating an urgent need for immediate expansion of MMT availability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519049     DOI: 10.1097/ADM.0b013e318287cfc9

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  16 in total

1.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

2.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

3.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

4.  Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.

Authors:  Tamara Beetham; Brendan Saloner; Sarah E Wakeman; Marema Gaye; Michael L Barnett
Journal:  Ann Intern Med       Date:  2019-06-04       Impact factor: 25.391

5.  Innovations in efforts to expand treatment for opioid use disorder.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2019-08-21       Impact factor: 4.018

6.  Interim Buprenorphine vs. Waiting List for Opioid Dependence.

Authors:  Stacey C Sigmon; Taylor A Ochalek; Andrew C Meyer; Bryce Hruska; Sarah H Heil; Gary J Badger; Gail Rose; John R Brooklyn; Robert P Schwartz; Brent A Moore; Stephen T Higgins
Journal:  N Engl J Med       Date:  2016-12-22       Impact factor: 91.245

Review 7.  The dynamic interaction between pain and opioid misuse.

Authors:  Adrianne R Wilson-Poe; Jose A Morón
Journal:  Br J Pharmacol       Date:  2017-06-28       Impact factor: 8.739

8.  Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.

Authors:  Stacey C Sigmon; Andrew C Meyer; Bryce Hruska; Taylor Ochalek; Gail Rose; Gary J Badger; John R Brooklyn; Sarah H Heil; Stephen T Higgins; Brent A Moore; Robert P Schwartz
Journal:  Addict Behav       Date:  2015-07-29       Impact factor: 3.913

9.  Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas.

Authors:  Marjorie Meyer; Julie Phillips
Journal:  Prev Med       Date:  2015-07-26       Impact factor: 4.018

10.  Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.

Authors:  Ajay Manhapra; Lantie Quinones; Robert Rosenheck
Journal:  Drug Alcohol Depend       Date:  2016-01-13       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.